Micafungin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Micafungin: From Invasive Candidiasis to Urinary Tract Infection
One-Sentence Summary
Micafungin is an echinocandin antifungal established for invasive candidiasis and candidemia. The TxGNN model predicts it may be effective for Urinary Tract Infection (Candida UTI/candiduria), with 0 clinical trials but 13 supporting publications — mostly case reports and small case series — currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Invasive candidiasis / candidemia (echinocandin antifungal; not captured in this evidence pack's license data) |
| Predicted New Indication | Urinary Tract Infection (Candida UTI) |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 (observational/retrospective cohort + case series, no RCTs) |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (data gap). Based on general pharmacological knowledge, micafungin belongs to the echinocandin antifungal class, which inhibits 1,3-β-D-glucan synthase, disrupting fungal cell wall synthesis. It is fungicidal against most Candida species, including azole-resistant strains, and its efficacy in invasive candidiasis/candidemia is well established.
The predicted new indication — Candida urinary tract infection (candiduria) — is mechanistically plausible because the causative organisms overlap heavily with micafungin's established spectrum (C. albicans, C. glabrata, C. krusei, C. auris). However, echinocandins have historically been considered a poor fit for UTIs due to low urinary excretion — most of the drug is metabolized hepatically with minimal unchanged renal clearance. The literature evidence base largely consists of case reports demonstrating that measurable urinary drug levels and clinical eradication can still occur, particularly when standard options (fluconazole, amphotericin B) are contraindicated or the organism is resistant.
Because this repurposing hypothesis runs counter to conventional PK teaching, the supporting evidence is important but currently limited to real-world case experience rather than controlled trials — this tempers confidence despite the very high TxGNN score.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27587066 | 2016 | Retrospective cohort | Int Urol Nephrol | Examined candiduria elimination rates among hospitalized patients treated with micafungin |
| 26937340 | 2016 | Case series | Med Mycol Case Rep | 5 patients received parenteral micafungin ≥6 days; fungal clearance within 30 days in all cases |
| 27424599 | 2016 | Case series | Int J Antimicrob Agents | 6 cases of UTI (4 fluconazole-resistant) successfully treated; urinary drug monitoring aided dosing |
| 35146837 | 2022 | Case series | Pediatr Int | Outcomes of critically ill PICU patients treated with micafungin for hospital-acquired Candida UTI |
| 38827222 | 2024 | Case report | Front Pediatr | Micafungin used to treat C. glabrata urinary infection in a premature neonate |
| 31111613 | 2019 | Case report + literature review | Transpl Infect Dis | Increased-dose micafungin eradicated chronic C. krusei UTI in a liver/kidney transplant recipient |
| 40765059 | 2025 | Case report | J Pharm Health Care Sci | C. glabrata pyelonephritis/bacteremia in an SGLT2-inhibitor patient successfully treated with micafungin |
| 38681664 | 2024 | Case report | Med Mycol Case Rep | Unilateral renal fungus ball (C. glabrata, micafungin-sensitive) managed with antifungal therapy + endoscopic extraction |
| 33520520 | 2020 | Case report | Cureus | Candida auris UTI in a multi-comorbid nursing home patient |
| 40405904 | 2025 | Case report | Cureus | Urosepsis from C. glabrata nephrolithiasis in an immunocompetent patient |
Finland Market Information
Micafungin is currently not marketed in Finland — no authorization records are available in this evidence pack (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (query status: not found).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by case reports and one retrospective cohort study (L3), with no clinical trials evaluating micafungin for UTI. More critically, safety data (TFDA/Fimea package insert warnings and contraindications) are flagged as a Blocking data gap, which by itself prevents entry into the S1 safety pre-assessment stage regardless of efficacy evidence strength.
To proceed, the following is needed:
- TFDA/Fimea package insert data (warnings, contraindications) — blocking gap, required before any S1 safety review
- Confirmed mechanism of action and original approved indication (currently data gap)
- Drug-drug interaction (DDI) profile
- Prospective or controlled studies specifically evaluating micafungin urinary pharmacokinetics and clinical outcomes in candiduria, given the drug's historically low unchanged renal excretion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.